Biotech Market Spotlight: HealthLinx
24 February, 2010 by Tim DeanUPDATED: Release of OvPlex ovarian cancer test in UK sends shares soaring.
Genetic Technologies hits U.S. firms with patent infringement
17 February, 2010 by Tim DeanPatent infringement suit brought against nine U.S. biotechnology companies for use of non-coding DNA technology.
QRxPharma initiates second pivotal phase III study of MoxDuo IR Dual-Opioid for NDA submission
10 February, 2010 by Staff WritersEvaluate analgesic efficacy and safety of MoxDuo IR in patients with moderate to severe post-operative pain following total knee replacement surgery.
Living Cell Technologies swaps license for portion of US company
10 February, 2010 by Staff WritersLiving Cell Technologies received 10 per cent of US startup, CytoSolv, in exchange for technology licence.
BioProspect a step closer to commercialising natural anti-termite repellent
08 February, 2010 by Tim DeanAPVMA registers Erimophilone Oil as an active ingredient, end-user product could be available within two years.
Australian biotech market watch 05/02/10
05 February, 2010 by Tim DeanCSL, ResMed, Living Cell Technology, Mesoblast, Prima BioMed, Sirtex Medical, CathRx
Another malaria breakthrough offers potential drug target
04 February, 2010 by Tim DeanResearchers at the WEHI have identified a protein that could present an attractive drug target to prevent the parasite's spread through the blood.
Australian biotech market watch 02/02/10
02 February, 2010 by Tim DeanCathRX, Mesoblast, ChemGenex, Living Cell Technologies, QRxPharma, CSL, ResMed, Cochlear
Promising anti-malaria target found
01 February, 2010 by Tim DeanAustralian and international researchers identify an enzyme that could prove an effective anti-malaria drug target.
Starpharma and Lilly sign new drug delivery collaboration
01 February, 2010 by Tim DeanLilly to use Starpharma's dendrimer drug delivery technology for human pharmaceuticals.
Biotech Market Spotlight: Patrys & CSL
28 January, 2010 by Tim DeanCollaboration between Patrys and CSL sends Patrys stocks soaring.
Prima BioMed new COO to drive CVac to market
25 January, 2010 by Tim DeanMatthew Lehman new chief operating officer for Prima BioMed will help commercialise CVac.
Australian biotech market watch 22/01/10
22 January, 2010 by Tim DeanMesoblast, Sirtex, Prima BioMed, pSivida, Cochlear, Living Cell Technology
BioProspect and Bio-Gene Technology sign agreement
21 January, 2010 by Staff WritersLicensing deal for natural insecticide, Qcide, assigned to Bio-Gene Technology.
Most malaria vaccine candidates haven't been investigated
19 January, 2010 by Tim DeanOnly a small fraction of proteins that could act as vaccine against blood-stage malaria candidates have been thoroughly studied, say WEHI scientists.
